These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30369183)

  • 21. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
    Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
    Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
    Wu XF; Li TT; Sun L; Wang LJ; Ran XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
    Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
    Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
    Hong M; Zhu H; Sun Q; Zhu Y; Miao Y; Yang H; Qiu HR; Li JY; Qian SX
    Aging (Albany NY); 2020 Apr; 12(7):5792-5811. PubMed ID: 32238611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Zhang Y; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):572-577. PubMed ID: 28810323
    [No Abstract]   [Full Text] [Related]  

  • 31. A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Wei Y; Wang L; Zhu C; Li H; Bo J; Zhang R; Lu N; Wu Y; Gao X; Dou L; Liu D; Gao C
    Med Oncol; 2023 Jan; 40(2):77. PubMed ID: 36625951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
    Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients.
    Wang L; Chu X; Wang J; An L; Liu Y; Li L; Xu J
    Turk J Haematol; 2021 Aug; 38(3):188-194. PubMed ID: 33938209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
    Ma XR; Wang J; Zhang WG; Chen YX; Cao XM; He AL; Liu J; Wang JL; Gu LF; Lei B; Zhang PY; Zhao WH; Yang Y; Wang FX; Xu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):369-74. PubMed ID: 25948187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
    Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
    Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.